Tributary Capital Management LLC Raises Stock Holdings in ICON Public Limited (NASDAQ:ICLR)

Tributary Capital Management LLC boosted its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 116.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,950 shares of the medical research company’s stock after acquiring an additional 2,122 shares during the quarter. Tributary Capital Management LLC’s holdings in ICON Public were worth $828,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Park Place Capital Corp lifted its holdings in shares of ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in ICON Public by 39.2% in the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 111 shares during the period. GAMMA Investing LLC lifted its stake in ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in shares of ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after buying an additional 96 shares during the period. Finally, First Horizon Advisors Inc. grew its stake in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Stock Down 1.1 %

Shares of NASDAQ ICLR opened at $200.48 on Friday. ICON Public Limited has a 1 year low of $183.38 and a 1 year high of $347.72. The company has a market capitalization of $16.54 billion, a price-to-earnings ratio of 22.35, a price-to-earnings-growth ratio of 1.52 and a beta of 1.20. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The business has a 50-day moving average of $209.54 and a two-hundred day moving average of $264.15.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The business had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the company earned $3.10 earnings per share. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, analysts forecast that ICON Public Limited will post 13.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on ICLR. Barclays lowered their target price on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. JPMorgan Chase & Co. lowered their price objective on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Robert W. Baird cut their target price on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Redburn Atlantic started coverage on shares of ICON Public in a report on Monday, October 14th. They set a “neutral” rating and a $311.00 target price on the stock. Finally, Leerink Partners restated an “outperform” rating and issued a $255.00 price target (down previously from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.